Drug intelligence / Profile preview

CS32497

Development stage: Unknown
Lead developer: Akeso
Modality: Small Molecules

Overview

CS32497 is a small molecule dual inhibitor of ALK2 (Activin receptor type 1) and ALK5 (Transforming growth factor beta receptor type 1) kinases, currently under development by Chipscreen Biosciences. These kinases are key mediators in the Bone Morphogenetic Protein (BMP) and Transforming Growth Factor-beta (TGF-β) signaling pathways, which regulate various cellular processes including erythropoiesis and iron metabolism. By dual inhibition of ALK2 and ALK5, CS32497 is intended to address ineffective erythropoiesis and reduce hepcidin expression, thereby treating anemia. The drug is currently being evaluated in Phase 1 clinical trials for the treatment of myelodysplastic syndromes (MDS) and associated anemia.

Targets

TGFBR1ACVR1 (Activin receptor type I)

Beyond the preview

Go deeper on CS32497.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CS32497.

Explore the full profile